论文部分内容阅读
目的观察佐芬普利、奥美沙坦、依普利酮对肾性高血压大鼠血压、心肌肥厚及外周血血管紧张素Ⅱ1型受体(AT1R)及其抗体(AT1R-Ab)的影响。方法 120只清洁型雄性SD大鼠随机分为假手术组、两肾一夹组、两肾一夹+佐芬普利组(Z)、两肾一夹+奥美沙坦组(O)和两肾一夹+依普利酮组(E),每组24只。对后4组以两肾一夹制作肾血管性高血压模型。制模4周后,药物干预组分别采用佐芬普利10mg/kg、奥美沙坦3mg/kg、依普利酮100mg/kg灌胃,假手术组、两肾一夹组以等体积蒸馏水灌胃。术后8、12、14周,超声心动图观察心脏结构和功能,每组处死6只大鼠取主动脉血;采用酶联免疫吸附技术(ELISA)检测血浆AT1R、AT1R-Ab水平。结果术后8周,假手术组、两肾一夹组的AT1R水平差异无统计学意义(P>0.05);各干预组AT1R水平较两肾一夹组上升(均P<0.05)。术后12周、14周两肾一夹组大鼠动脉血浆AT1R水平较同期假手术组上调;Z、E干预组AT1R水平较两肾一夹组升高[12周:(74.63±0.83)、(75.85±3.09)比(67.56±1.67)ng/L;14周:(78.29±0.31)、(78.05±1.12)比(73.90±1.98)ng/L,均P<0.05];而O组与两肾一夹组差异无统计学意义(P>0.05)。术后8周,两肾一夹组大鼠血浆AT1R-Ab水平较假手术组升高;术后12、14周两肾一夹组大鼠血浆AT1R-Ab水平较术后8周降低;各时段Z、E组AT1R-Ab水平均较两肾一夹组降低[8周(2.10±0.10)、(2.13±0.18)比(2.75±0.13)ng/L,12周(2.00±0.10)、(2.03±0.1)比(2.32±0.10)ng/L;14周(1.99±0.16)、(2.00±0.09)比(2.23±0.23)ng/L;均P<0.05];而O组与两肾一夹组差异无统计学意义(P>0.05)。结论肾性高血压大鼠血压、血浆AT1R、AT1-Ab水平随时间动态变化。奥美沙坦、佐芬普利、依普利酮降低大鼠血压、减小心肌肥厚程度、上调动脉血AT1R水平;佐芬普利、依普利酮下调动脉血浆AT1R-Ab水平,而奥美沙坦对AT1R-Ab无明显影响。
Objective To observe the effects of zofenopril, olmesartan and eplerenone on blood pressure, cardiac hypertrophy and the levels of peripheral blood angiotensin Ⅱ type 1 receptor (AT1R) and its antibody (AT1R-Ab) in renal hypertensive rats. Methods One hundred and twenty male SD rats were randomly divided into sham-operated group, two-kidney one-clip group, two-kidney one-clip plus zofenopril group (Z), two kidney one clip plus olmesartan group (O) and two Kidney a folder + eplerenone group (E), each group 24. After 4 groups with two kidneys and a clip made of renal vascular hypertension model. Four weeks after model establishment, the drug intervention groups were treated with zofenopril 10 mg / kg, olmesartan 3 mg / kg, and eplerenone 100 mg / kg orally, respectively. stomach. Cardiac structure and function were observed by echocardiography at 8th, 12th and 14th week after operation. Six rats in each group were sacrificed and the levels of AT1R and AT1R-Ab were measured by enzyme-linked immunosorbent assay (ELISA). Results There was no significant difference in the AT1R levels between the sham-operated group and the two-kidney-one-clamp group at 8 weeks after operation (P> 0.05). The levels of AT1R in both intervention groups were significantly higher than those in the two groups (all P <0.05). The level of AT1R in arterial plasma of rats in two kidney and one clamp group was higher than that in sham operation group at 12 weeks and 14 weeks after operation. The level of AT1R in Z and E intervention group was higher than that in two kidney and one clamp group [(12): (74.63 ± 0.83) (75.85 ± 3.09) vs (67.56 ± 1.67) ng / L, 14 weeks: (78.29 ± 0.31), (78.05 ± 1.12) vs (73.90 ± 1.98) ng / L, all P <0.05] There was no significant difference between the two groups (P> 0.05). At 8 weeks after operation, plasma levels of AT1R-Ab in two kidney and one clamp group were significantly higher than those in sham-operation group. Plasma levels of AT1R-Ab in two kidney and one clamp group were lower than those in the control group at 8 and 12 weeks after operation The levels of AT1R-Ab in group Z and group E were significantly lower than those in group B and C (2.10 ± 0.10, 2.13 ± 0.18, 2.75 ± 0.13, 2.00 ± 0.10, 2.03 ± 0.1) was significantly higher than that of the control group (2.32 ± 0.10) ng / L; the scores of the 14th week (1.99 ± 0.16) and (2.00 ± 0.09) There was no significant difference between the clamp groups (P> 0.05). Conclusion The levels of blood pressure, plasma AT1R and AT1-Ab levels in renal hypertensive rats change with time. Olmesartan, zofenopril, and eplerenone reduced blood pressure, decreased the level of myocardial hypertrophy and raised the level of AT1R in arterial blood. Zofenopril and eplerenone decreased the levels of AT1R-Ab in arterial plasma, Tan had no significant effect on AT1R-Ab.